Chang B. Hong

Chang is the founding member of Modality Law, a law firm focused on advising life sciences and emerging technology companies. He has over two decades of experience, having served as in-house counsel for private and public biotechnology, pharmaceutical, renewable fuels, and high-tech companies. As a co-founder of biotech and sustainability companies, he has hands-on experience and a deep understanding of legal, R&D, operations, and commercialization activities.

Chang’s practice spans corporate transactions, including licensing, corporate financing, governance, compliance, and company formations; IP strategy and development, including pre-litigation counseling, patent prosecution and portfolio development, due diligence, product clearance, and opinions; trade secret management; trademark prosecution; as well as regulatory and clinical matters. He has counseled clients on glycoprotein therapeutics, gene therapies, nucleic acid delivery, therapeutic antibodies, cell therapies, peptides, virology, small molecules, medical devices, biofuel production, renewable chemicals production, synthetic biology, agbio, foodtech, and machine learning for various technologies. Leveraging his in-house experience, he serves as general counsel to a number of clients.

With extensive experience in intellectual property and transactional law, Chang has advised clients across the life sciences, biotechnology, and high-tech industries on strategic partnerships, licensing, and IP portfolio development. He has led high-value transactions, including multi-million-dollar AI-driven therapeutics and polymer nanoparticle deals, structured licensing agreements for cutting-edge platform technologies, and managed foundational IP transactions for university spin-offs. As in-house counsel for emerging companies, he has built global patent estates, guided financing efforts, and overseen corporate rebranding initiatives. His experience also includes counseling on complex litigation strategies, first-to-file product evaluations, and commercialization pathways for pharmaceuticals, bioethanol, and food technology.